查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1397048

腫瘤消融市場：按技術、治療和應用分類：2022-2032 年全球機會分析和產業預測

Tumor Ablation Market By Technology, By Treatment, By Application : Global Opportunity Analysis and Industry Forecast, 2022-2032
出版日期: | 出版商: Allied Market Research | 英文 240 Pages | 商品交期: 2-3個工作天內

價格

2022年腫瘤消融市值為14.1385億美元，預計2032年將達到50.3244億美元，2022年至2032年的年複合成長率為13.5%。

腫瘤消融技術，也稱為微創技術，用於治療腎臟、骨骼、肝臟和肺部的腫瘤。它利用熱量來瞄準特定的癌細胞。這種針狀裝置含有一種發熱成分，可以殺死目標癌細胞。它是在體內進行的，無需將腫瘤從體內切除。

這種方法透過插入探針並在精確的電腦斷層掃描下將其加熱至攝氏 100 度來去除良性腫瘤。有多種腫瘤消融方法可用於診斷和治療疾病，包括微波消融、射頻消融和冷凍。重複使用消融技術可以減輕患者的疼痛和風險，提高精確度，並治療更廣泛的癌症類型。

全球腫瘤消融市場的成長主要是由於癌症盛行率的不斷上升以及腫瘤消融治療的高採用率所推動的。此外，技術先進的腫瘤消融技術的採用和出現，例如熱感消融、雷射消熔、不可逆電穿孔以及高強度聚焦超音波（HIFU）的出現，都是影響市場成長的因素。提高消融技術使用的安全性、增加老年人口以及增加公私舉措和資金以支持與腫瘤消融相關的持續研究活動正在推動市場成長。

癌症是一種毀滅性且可能危及生命的疾病，在世界各地的發病率正在穩步上升。例如，根據國家衛生統計中心的數據。這種激增是由於多種因素造成的，包括高齡化、生活方式的改變以及能夠更早發現腫瘤的診斷技術的改進。腫瘤消融技術在腫瘤學領域引起了廣泛關注，因為它們無需進行大量手術即可破壞癌組織。

此外，腫瘤消融技術通常用於不適合手術的患者或作為緩解晚期癌症症狀的安寧療護。癌症盛行率的增加不僅增加了對腫瘤消融手術的需求，而且刺激了持續的研究和開發工作，以提高這些治療方法的有效性和可及性。由此，腫瘤消融市場的技術創新加速，先進技術和設備的引進，進一步推動了市場成長。因此，癌症盛行率的增加預計將推動市場成長。

此外，基於腫瘤消融的治療方法的高採用率已成為腫瘤消融市場成長的關鍵驅動力。近年來，射頻消融（RFA）、微波消融、冷凍等腫瘤消融技術因其對肝腫瘤、肺腫瘤、腎腫瘤、骨腫瘤等多種腫瘤的有效治療而受到廣泛歡迎。 。與傳統手術方法相比，腫瘤消融技術有幾個明顯的優勢。它是微創的，這意味著切口很小，或者在某些情況下根本沒有切口。這可以縮短復健時間、縮短住院時間並減少術後併發症，使其成為對患者和醫療保健提供者都有吸引力的選擇。

例如，美國國家醫學圖書館 2021 年的一份報告發現，對於孤立性肝細胞癌，經皮消融是安全的，幾乎與手術一樣有效，通常成本更低，住院時間更短。據報道，這已經足夠了。此外，技術和影像的進步顯著提高了腫瘤消融手術的精確度和準確性。超音波、 電腦斷層掃描和MRI等即時影像引導使醫療專業人員能夠在切除過程中精確瞄準和監測腫瘤，在切除癌組織的同時不傷害周圍健康的器官和組織，從而可以徹底破壞腫瘤。因此，基於腫瘤消融的治療方法的採用預計將激增，從而對市場成長做出重大貢獻。

然而，與腫瘤消融治療相關的副作用可能會抑制市場成長。此外，腫瘤消融領域研發活動的活性化預計將為市場提供重大成長機會。腫瘤消融市場按技術、治療、應用和地區細分。依技術分為射頻消融術、微波消融、冷凍、不可逆電穿孔消融等。治療方法分為手術消融、腹腔鏡消融、經皮消融。依用途分為腎癌、肝癌、乳癌、肺癌、攝護腺癌和骨癌。依區域分類，在北美（美國、加拿大、墨西哥）、歐洲（美國、加拿大、墨西哥）、北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙、亞洲其他地區）進行分析-太平洋）。亞太地區（日本、中國、澳洲、印度、韓國、亞太地區其他地區）和LAMEA（巴西、南非、沙烏地阿拉伯、其他歐洲國家）。全球腫瘤消融市場的主要企業有美敦力公司、波士頓科學公司、史密斯和樂輝公司、Integra LifeSciences Holding Corporation、AngioDynamics Inc、HealthTronics, Inc、Bioventus (Misonix Inc)、強生公司、ConMed Corporation、奧林巴斯公司。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 全球癌症盛行率不斷上升。
      • 對微創腫瘤消融技術的需求不斷增加
    • 抑制因素
      • 與腫瘤消融治療相關的副作用
    • 機會
      • 活性化腫瘤消融的研發活動

第4章腫瘤消融市場：依技術分類

  • 概述
  • 射頻消融術
  • 微波消融
  • 冷凍
  • 不可逆電穿孔消融
  • 其他消融技術

第5章腫瘤消融市場：依治療方式

  • 概述
  • 手術消融
  • 腹腔鏡消融術
  • 經皮術

第6章腫瘤消融市場：依應用分類

  • 概述
  • 腎癌
  • 肝癌
  • 乳癌
  • 肺癌
  • 攝護腺癌
  • 骨癌

第7章腫瘤消融市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Medtronic plc
  • Boston Scientific Corporation
  • Smith & Nephew plc
  • AngioDynamics, Inc.
  • HealthTronics, Inc.
  • Bioventus LLC
  • Johnson & Johnson
  • ConMed Corporation
  • Olympus Corporation
  • Integra LifeSciences Holdings Corporation
Product Code: A17208

The tumor ablation market was valued at $1,413.85 million in 2022 and is estimated to reach $5,032.44 million by 2032, exhibiting a CAGR of 13.5% from 2022 to 2032. Tumor ablation techniques, also referred to as minimally invasive technology, are used to treat tumors of kidney, bones, liver, and lungs. They use heat to target a specific tumor cell. It is a needle-like device with a heat-generating component that leads to cellular necrosis of targeted tumor cell. It is performed in-vivo, without taking tumors out of the body.

The method eliminates benign tumors by inserting a probe and heating it to 100 degrees Celsius under precise computer tomography. There are different methods available for tumor ablation such as microwave ablation, radiofrequency ablation, cryoablation, and others that can be used for disease diagnosis and treatment. Repeated use of ablation methods helps reduce patient's pain and risk while increasing accuracy and treating a broader type of cancer.

The growth of the global tumor ablation market is majorly driven by increase in prevalence of cancer, and high adoption of the tumor ablation-based treatments. Moreover, adoption and emergence of technologically advanced tumor ablation techniques including the advent of thermal and laser ablation, irreversible electroporation, and high-intensity focused ultrasound (HIFU) are the factors that influence the market growth. Increase in safety regarding use of ablation techniques, increase in geriatric population, and increase in public-private initiatives & funding to support ongoing research activities related to tumor ablation drive the market growth.

Cancer, a devastating and potentially life-threatening disease, has been steadily increasing in incidence across the globe. For instance, according to the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S. This surge can be attributed to several factors, including an aging population, lifestyle changes, and improved diagnostics that enable earlier detection of tumors. Tumor ablation techniques have gained significant prominence in the field of oncology due to their ability to destroy cancerous tissue without the need for extensive surgeries.

Additionally, tumor ablation techniques are often utilized for patients who are not candidates for surgery or as a palliative option to relieve symptoms in advanced cancer cases. The increasing prevalence of cancer not only drives the demand for tumor ablation procedures but also stimulates ongoing research and development efforts to enhance the efficacy and accessibility of these treatments. This, in turn, fosters innovation in the tumor ablation market, leading to the introduction of advanced technologies and improved devices, which further boosts market growth. Thus, the rise in prevalence of cancer is expected to drive the growth of the market.

Furthermore, the high adoption of tumor ablation-based treatments has emerged as a major driving factor for the growth of the tumor ablation market. Tumor ablation techniques, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have gained significant popularity in recent years due to their effectiveness in treating various types of tumors, including liver, lung, kidney, and bone tumors. Tumor ablation procedures offer several distinct advantages over traditional surgical methods. They are minimally invasive, which means they involve smaller incisions or, in some cases, no incisions at all. This results in shorter recovery times, reduced hospital stays, and lower post-operative complications, making them more attractive options for both patients and healthcare providers.

For instance, according to a 2021 report by the National Library of Medicine, it was reported that percutaneous ablation is safe and nearly as efficacious as surgery, usually requiring a lower cost and shorter hospital stay for single hepatocellular carcinoma. In addition, advancements in technology and imaging have greatly improved the precision and accuracy of tumor ablation procedures. Real-time imaging guidance, such as ultrasound, CT scans, or MRI, allows medical professionals to precisely target and monitor the tumor during the ablation process, ensuring thorough destruction of the cancerous tissue while sparing healthy surrounding organs and tissues. Thus, the surge in adoption of tumor ablation-based treatments is expected to significantly contribute to the growth of the market.

However, side-effects associated with tumor ablation treatment might restrain the growth of the market. Moreover, a rise in research and development activities for tumor ablation is expected to present significant growth opportunities to the market. The tumor ablation market is segmented on the basis of technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. By treatment, it is classified into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, it is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer and bone cancer. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major key players that operate in the global tumor ablation market are Medtronic plc, Boston Scientific Corporation, Smith and Nephew PLC, Integra LifeSciences Holding Corporation, AngioDynamics Inc, HealthTronics, Inc, Bioventus (Misonix Inc), Johnson and Johnson, ConMed Corporation and Olympus Corporation.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tumor ablation market analysis from 2022 to 2032 to identify the prevailing tumor ablation market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the tumor ablation market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global tumor ablation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Technology

  • Radiofrequency Ablation
  • Microwave Ablation
  • Cryoablation
  • Irreversible Electroporation Ablation
  • Other Ablation Technologies

By Treatment

  • Surgical Ablation
  • Laparoscopic Ablation
  • Percutaneous Ablation

By Application

  • Kidney Cancer
  • Liver Cancer
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Bone Cancer

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Olympus Corporation
    • AngioDynamics, Inc.
    • Bioventus LLC
    • Johnson & Johnson
    • Medtronic plc
    • ConMed Corporation
    • Smith & Nephew plc
    • Integra LifeSciences Holdings Corporation
    • HealthTronics, Inc.
    • Boston Scientific Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of cancers across the globe.
      • 3.4.1.2. Increase in demand for minimally invasive tumor ablation techniques.
    • 3.4.2. Restraints
      • 3.4.2.1. Side-effects associated with tumor ablation treatment.
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in research and development activities for tumor ablation.

CHAPTER 4: TUMOR ABLATION MARKET, BY TECHNOLOGY

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Radiofrequency Ablation
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Microwave Ablation
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Cryoablation
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Irreversible Electroporation Ablation
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Other Ablation Technologies
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: TUMOR ABLATION MARKET, BY TREATMENT

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Surgical Ablation
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Laparoscopic Ablation
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Percutaneous Ablation
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: TUMOR ABLATION MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Kidney Cancer
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Liver Cancer
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Breast Cancer
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Lung Cancer
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country
  • 6.6. Prostate Cancer
    • 6.6.1. Key market trends, growth factors and opportunities
    • 6.6.2. Market size and forecast, by region
    • 6.6.3. Market share analysis by country
  • 6.7. Bone Cancer
    • 6.7.1. Key market trends, growth factors and opportunities
    • 6.7.2. Market size and forecast, by region
    • 6.7.3. Market share analysis by country

CHAPTER 7: TUMOR ABLATION MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Technology
    • 7.2.3. Market size and forecast, by Treatment
    • 7.2.4. Market size and forecast, by Application
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Technology
      • 7.2.5.1.2. Market size and forecast, by Treatment
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Technology
      • 7.2.5.2.2. Market size and forecast, by Treatment
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Technology
      • 7.2.5.3.2. Market size and forecast, by Treatment
      • 7.2.5.3.3. Market size and forecast, by Application
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Technology
    • 7.3.3. Market size and forecast, by Treatment
    • 7.3.4. Market size and forecast, by Application
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Technology
      • 7.3.5.1.2. Market size and forecast, by Treatment
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Technology
      • 7.3.5.2.2. Market size and forecast, by Treatment
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Technology
      • 7.3.5.3.2. Market size and forecast, by Treatment
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Technology
      • 7.3.5.4.2. Market size and forecast, by Treatment
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Technology
      • 7.3.5.5.2. Market size and forecast, by Treatment
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Technology
      • 7.3.5.6.2. Market size and forecast, by Treatment
      • 7.3.5.6.3. Market size and forecast, by Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Technology
    • 7.4.3. Market size and forecast, by Treatment
    • 7.4.4. Market size and forecast, by Application
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Technology
      • 7.4.5.1.2. Market size and forecast, by Treatment
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Technology
      • 7.4.5.2.2. Market size and forecast, by Treatment
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Market size and forecast, by Technology
      • 7.4.5.3.2. Market size and forecast, by Treatment
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.4. India
      • 7.4.5.4.1. Market size and forecast, by Technology
      • 7.4.5.4.2. Market size and forecast, by Treatment
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Technology
      • 7.4.5.5.2. Market size and forecast, by Treatment
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Technology
      • 7.4.5.6.2. Market size and forecast, by Treatment
      • 7.4.5.6.3. Market size and forecast, by Application
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Technology
    • 7.5.3. Market size and forecast, by Treatment
    • 7.5.4. Market size and forecast, by Application
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Technology
      • 7.5.5.1.2. Market size and forecast, by Treatment
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Technology
      • 7.5.5.2.2. Market size and forecast, by Treatment
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Technology
      • 7.5.5.3.2. Market size and forecast, by Treatment
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Technology
      • 7.5.5.4.2. Market size and forecast, by Treatment
      • 7.5.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Medtronic plc
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Boston Scientific Corporation
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Smith & Nephew plc
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. AngioDynamics, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. HealthTronics, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Bioventus LLC
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Johnson & Johnson
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. ConMed Corporation
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Olympus Corporation
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Integra LifeSciences Holdings Corporation
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 02. TUMOR ABLATION MARKET FOR RADIOFREQUENCY ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. TUMOR ABLATION MARKET FOR MICROWAVE ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. TUMOR ABLATION MARKET FOR CRYOABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. TUMOR ABLATION MARKET FOR IRREVERSIBLE ELECTROPORATION ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. TUMOR ABLATION MARKET FOR OTHER ABLATION TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 08. TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 12. TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. TUMOR ABLATION MARKET FOR BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. TUMOR ABLATION MARKET FOR PROSTATE CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. TUMOR ABLATION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. U.S. TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 24. U.S. TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 25. U.S. TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 27. CANADA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 28. CANADA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. UK TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 43. UK TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 44. UK TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. ITALY TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 46. ITALY TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 47. ITALY TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 49. SPAIN TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 50. SPAIN TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. CHINA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 62. CHINA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 63. CHINA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. INDIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 68. INDIA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 69. INDIA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH KOREA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 77. LAMEA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 78. LAMEA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. LAMEA TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 80. BRAZIL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 81. BRAZIL TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 82. BRAZIL TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. SAUDI ARABIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 84. SAUDI ARABIA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 85. SAUDI ARABIA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH AFRICA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH AFRICA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH AFRICA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LAMEA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 90. REST OF LAMEA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 91. REST OF LAMEA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 93. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 94. MEDTRONIC PLC: PRODUCT SEGMENTS
  • TABLE 95. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 96. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 97. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 98. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
  • TABLE 99. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 100. SMITH & NEPHEW PLC: KEY EXECUTIVES
  • TABLE 101. SMITH & NEPHEW PLC: COMPANY SNAPSHOT
  • TABLE 102. SMITH & NEPHEW PLC: PRODUCT SEGMENTS
  • TABLE 103. SMITH & NEPHEW PLC: PRODUCT PORTFOLIO
  • TABLE 104. ANGIODYNAMICS, INC.: KEY EXECUTIVES
  • TABLE 105. ANGIODYNAMICS, INC.: COMPANY SNAPSHOT
  • TABLE 106. ANGIODYNAMICS, INC.: PRODUCT SEGMENTS
  • TABLE 107. ANGIODYNAMICS, INC.: PRODUCT PORTFOLIO
  • TABLE 108. ANGIODYNAMICS, INC.: KEY STRATERGIES
  • TABLE 109. HEALTHTRONICS, INC.: KEY EXECUTIVES
  • TABLE 110. HEALTHTRONICS, INC.: COMPANY SNAPSHOT
  • TABLE 111. HEALTHTRONICS, INC.: PRODUCT SEGMENTS
  • TABLE 112. HEALTHTRONICS, INC.: PRODUCT PORTFOLIO
  • TABLE 113. BIOVENTUS LLC: KEY EXECUTIVES
  • TABLE 114. BIOVENTUS LLC: COMPANY SNAPSHOT
  • TABLE 115. BIOVENTUS LLC: PRODUCT SEGMENTS
  • TABLE 116. BIOVENTUS LLC: PRODUCT PORTFOLIO
  • TABLE 117. BIOVENTUS LLC: KEY STRATERGIES
  • TABLE 118. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 119. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 120. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 121. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 122. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 123. CONMED CORPORATION: KEY EXECUTIVES
  • TABLE 124. CONMED CORPORATION: COMPANY SNAPSHOT
  • TABLE 125. CONMED CORPORATION: PRODUCT SEGMENTS
  • TABLE 126. CONMED CORPORATION: PRODUCT PORTFOLIO
  • TABLE 127. OLYMPUS CORPORATION: KEY EXECUTIVES
  • TABLE 128. OLYMPUS CORPORATION: COMPANY SNAPSHOT
  • TABLE 129. OLYMPUS CORPORATION: PRODUCT SEGMENTS
  • TABLE 130. OLYMPUS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 131. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 132. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 133. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT SEGMENTS
  • TABLE 134. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 135. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. TUMOR ABLATION MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF TUMOR ABLATION MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN TUMOR ABLATION MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN TUMOR ABLATION MARKET (2022-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL TUMOR ABLATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR RADIOFREQUENCY ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR MICROWAVE ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR CRYOABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR IRREVERSIBLE ELECTROPORATION ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR OTHER ABLATION TECHNOLOGIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. TUMOR ABLATION MARKET, BY TREATMENT, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. TUMOR ABLATION MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR LIVER CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR BREAST CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR LUNG CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR PROSTATE CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR BONE CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. TUMOR ABLATION MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 29. U.S. TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. CANADA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. MEXICO TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. GERMANY TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. FRANCE TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. UK TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. ITALY TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SPAIN TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF EUROPE TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. JAPAN TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. CHINA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. AUSTRALIA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. INDIA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SOUTH KOREA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. BRAZIL TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. SAUDI ARABIA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SOUTH AFRICA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. REST OF LAMEA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52. COMPETITIVE DASHBOARD
  • FIGURE 53. COMPETITIVE HEATMAP: TUMOR ABLATION MARKET
  • FIGURE 54. TOP PLAYER POSITIONING, 2022
  • FIGURE 55. MEDTRONIC PLC: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 56. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 57. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 58. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. SMITH & NEPHEW PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 62. SMITH & NEPHEW PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. SMITH & NEPHEW PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. ANGIODYNAMICS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. ANGIODYNAMICS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. ANGIODYNAMICS, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. BIOVENTUS LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. BIOVENTUS LLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. CONMED CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. CONMED CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. OLYMPUS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 75. OLYMPUS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 76. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 77. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 78. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)